Search Results for "Myeloma Mils"
Original Source: A novel role of IL-17 producing lymphocytes in mediating lytic bone disease in multiple myeloma.
Osteoclast (OC) mediated lytic bone disease remains a cause of major morbidity in multiple myeloma (MM). Here we demonstrate the critical role of IL-17 producing marrow infiltrating lymphocytes (MILs) in OC activation and development of bone lesions in myeloma patients. Unlike MILs from normal bone marrow, myeloma MILs possess few regulatory T cells (Tregs) and demonstrate an IL-17 phenotype which enhances OC activation. In univariate analyses of factors mediating bone destruction, levels of cytokines that...
Matching Channels
Myeloma is a malignant disease of the bone marrow. The features are an excess of abnormal malignant plasma cells in the bone marrow, lytic deposits on an X-ray and abnormal gammaglobulin in the seru...
The European Organization for Rare Diseases considers orphan diseases to be those that are rare (occur in 1 in 1500 to 1 in 2500 patients, according to US Rare Disease Act 2002 and European Commissi...
Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid...
The proteasome is involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune respon...
Matching News
Myeloma UK Funded Research Leads To Breakthrough In Understanding Causes Of Myeloma Cancer
The Myeloma UK funded Research Programme at The Institute of Cancer Research (ICR) has made another important discovery about the genetics of myeloma. Researchers at the ICR have identified an inherit...
Myeloma bone disease: background and latest
Prof Evangelos Terpos and Prof Michel Delforge talk at the 14th International Myeloma Workshop, 3-7th May 2013, Kyoto. Myeloma bone disease (MBD) is the most common complication of multiple myeloma (...
ecancertv talks to Eric Low at IMW 2013, Kyoto, Japan, 3-7th April Myeloma UK is a registered charity and is the only organisation in the UK dealing exclusively with myeloma. They are attending IMW...
Bristol-Myers Squibb joins Multiple Myeloma Research Foundation for multiple myeloma treatment
The Multiple Myeloma Research Foundation announced that Bristol-Myers Squibb has joined the MMRF pre-competitive consortium to discover and accelerate new approaches to treating multiple myeloma throu...
New drug for multiple myeloma could be available within next few months in Europe
The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - today said the newest drug for treating multiple myeloma could be...
FDA's approval of Kyprolis offers hope to myeloma patients, says IMF
The International Myeloma Foundation (IMF) - the oldest and largest foundation dedicated to improving the life and care of myeloma patients - says today's Food and Drug Administration approval of Onyx...
Dr Hiroshi Kosugi, Director of the Department of Haematology at Ogaki Municipal Hospital, and Vice President of the IMW 2013 Kyoto meeting talks to ecancertv about the Japan Myeloma Network, clincial...
Recent advances in multiple myeloma, featuring Educational Updates from ASH 2012
Professor Gareth Morgan from London, UK, leads an expert panel discussing key topics from the Multiple Myeloma Debate 2012 in Berlin for ecancer.TV, as well as the changing treatment landscape in mult...
Matching PubMed Articles
A novel role of IL-17 producing lymphocytes in mediating lytic bone disease in multiple myeloma.
Osteoclast (OC) mediated lytic bone disease remains a cause of major morbidity in multiple myeloma (MM). Here we demonstrate the critical role of IL-17 producing marrow infiltrating lymphocytes (MILs)...
Abstract Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment since the disease is not curable using current chemotherapeutic regimens. The aim of t...
The graft-versus-myeloma (GVM) effect represents a powerful form of immune attack exerted by alloreactive T cells against multiple myeloma cells, which leads to clinical responses in multiple myeloma...
United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its efficacy in both the upfront and relapse settings,...
Extramedullary Multiple Myeloma.
Abstract Extramedullary disease (EMD), defined as a clonal plasmacytic infiltrate at anatomic sites distant from the bone marrow or adjacent soft tissue in a patient with underlying multiple myeloma,...
